%PDF-1.3
%
6 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
21 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
20 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
7 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
13 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
22 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
15 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
14 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
19 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
18 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
11 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
17 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
3 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
16 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
1 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
10 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
12 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
4 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
8 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
5 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
9 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
24 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2015-06-15T05:21:32-07:00
2015-05-27T14:58:02+05:30
application/pdf
APC-2014-0309-ver9-Krsak_3P 307..313
uuid:c53d9d7d-5cbd-4649-b8ee-7387f782cb9f
uuid:b9985eb4-cf85-4628-922d-9fac33235b8c
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bih] D. pa
endstream
endobj
31 0 obj
<>stream
x+ |
endstream
endobj
32 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
33 0 obj
<>stream
x+ |
endstream
endobj
34 0 obj
<>stream
xS**T0T0 BiU !D. _e1
endstream
endobj
35 0 obj
<>stream
x+ |
endstream
endobj
36 0 obj
<>stream
xS**T0T0 Bih]D. r^j
endstream
endobj
37 0 obj
<>stream
x+ |
endstream
endobj
38 0 obj
<>stream
xS**T0T0 Bih]9D. qaj
endstream
endobj
41 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 1 k
0 Tc
0 Tw
[(infected)-352.4(patients,)]TJ
7.3823 0 0 6.5614 130.5637 729.5242 Tm
(20)Tj
9.843 0 0 9.843 141.3921 725.1588 Tm
[(while)-347.6(other)-346.6(studies)-354.3(have)-346.6(failed)-349(to)-347.9(show)]TJ
-8.0636 -1.1174 TD
[(benets)-297.8(on)-290.2(mortality,)]TJ
7.3823 0 0 6.5614 147.0614 718.5825 Tm
(21)Tj
9.843 0 0 9.843 157.3228 714.1605 Tm
[(or)-295.9(mortality)-295(and)-292.5(cardiovascular)-297.7(out-)]TJ
-9.6821 -1.1116 TD
(comes.)Tj
7.3823 0 0 6.5614 89.6882 707.5841 Tm
(22)Tj
9.843 0 0 9.843 100.6866 703.2188 Tm
[(The)-368.5(latter)-366.4(study,)]TJ
7.3823 0 0 6.5614 167.4141 707.5841 Tm
(22)Tj
9.843 0 0 9.843 178.4125 703.2188 Tm
[(however,)-365.7(showed)-365.6(a)-365.1(signicant)]TJ
-11.8247 -1.1116 TD
[(association)-199.9(between)-196.5(statins)-198.9(and)-194.5(a)-192.3(decreased)-199.8(incidence)-199.1(of)-192.2(non-)]TJ
T*
[(AIDS)-247.9(dening)-245(malignancies.)-253.1(No)-245(results)-250.6(of)-244.1(randomized)-252(trials)]TJ
0 -1.1174 TD
[(have)-283.2(been)-283.2(reported)-281.9(so)-278.5(far.)]TJ
1.0137 -1.1116 TD
[(Using)-363.4(data)-364(from)-368.4(a)-359.4(prospective)-367(cohort)-365(of)-365(PLWH,)-363.4(we)-367.1(ex-)]TJ
-1.0137 -1.1116 TD
[(amined)-275.2(the)-275.3(association)-274.8(of)-272.9(statins)-273.8(with)-270.5(the)-275.3(risk)-275(of)-267.1(developing)]TJ
0 -1.1174 TD
[(MI,)-283(stroke,)-281.8(and)-280.9(all-cause)-285.3(mortality.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 62.022 615.5715 Tm
(Methods)Tj
/F9 1 Tf
0 -1.8336 TD
[(Cohort)-337.9(description)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 582.6896 Tm
[(The)-489.5(Nutrition)-489.3(For)-486.9(Healthy)-489.2(Living)-491.9(\(NFHL\))-487.4(cohort)-491.7(was)]TJ
-1.0137 -1.1116 TD
[(initiated)-370(in)-370.9(1995)-367.3(to)-365.2(examine)-375.4(the)-367.5(nutritional)-371(status)-370.5(and)-367.3(me-)]TJ
0 -1.1174 TD
[(tabolism)-408.8(in)-405.5(a)-405.4(representative)-407.3(cohort)-411(of)-399.6(HIV-infecte)-11.8(d)-404.3(adults)]TJ
0 -1.1116 TD
[(from)-420.3(Massachusetts.)-426(Since)-416.7(1995,)-422.5(881)-412.2(HIV)-425.5(infected)-421.5(adults)]TJ
T*
[(have)-398.4(been)-392.6(enrolled)-397.3(on)-393.9(a)-393.9(rolling)-394(basis.)-395.7(The)-391.6(NFHL)-398.8(patients)]TJ
0 -1.1174 TD
[(were)-433.8(followed)-431.5(for)-429.5(HIV)-431.2(\(and)-431.8(its)-429.6(outcomes\),)-431.5(other)-433(medical)]TJ
0 -1.1116 TD
[(conditions,)-413.2(dietary)-413.4(intake,)-410(medications,)-417.9(body)-407.6(composition,)]TJ
T*
[(quality)-464.3(of)-462.9(life,)-464.2(liver)-461.9(function,)-462.9(serum)-468.4(glucose,)-462.7(and)-465.2(insulin)]TJ
0 -1.1174 TD
[(levels)-389.1(initially)-392(via)-384.7(6-monthly)-391.5(visits,)-384.4(and)-390.4(later)-388.2(on)-388.1(annually.)]TJ
0 -1.1116 TD
[(The)-357(exclusion)-357.9(criteria)-358.2(for)-354.6(NFHL)-352.8(included)-357(diabetes,)-361.4(uncon-)]TJ
T*
[(trolled)-516.1(hypertension,)-520.1(and)-511.3(myocardial)-517.1(infarction)-520.5(or)-514.8(stroke)]TJ
0 -1.1174 TD
[(within)-405.3(the)-402(past)-402.9(6)-398.5(months.)-402.9(But)-401.9(participants)-402.9(who)-401.6(developed)]TJ
0 -1.1116 TD
[(these)-284.2(conditions)-288.8(after)-284.4(enrollment)-291.4(continued)-283.2(in)-284.6(the)-286.8(study)-281.9(and)]TJ
T*
[(were)-324.4(consented)-324.4(for)-325.8(the)-321.4(CARE)-325.3(sub-study,)-318.3(which)-324.5(focused)-326.6(on)]TJ
T*
[(cardiovascular)-286.2(health.)-277.6(The)-282.1(CARE)-279.2(subset)-278.2(was)-275.9(begun)-283.1(in)-273(2000)]TJ
0 -1.1174 TD
[(and)-724.4(enrolled)-725.6(any)-724.4(consenting)-727.6(NFHL)-727.1(participants)-731.2(\(total)]TJ
/F6 1 Tf
0 -1.1116 TD
(n)Tj
/F5 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(345\).)-284.3(The)-293.6(initiation)-289.4(of)-290.2(this)-286.7(subcohort)-293.2(reected)-289.9(a)-290.2(new)-287.6(era)]TJ
-1.3881 -1.1116 TD
[(for)-250.9(the)-246.5(monitoring)-248.8(of)-249.8(HIV-infected)-249(patients)-253.2(in)-244.2(general.)-250.9(From)]TJ
0 -1.1174 TD
[(September)-325.6(of)-324.7(2000)-321.2(on,)-322.4(the)-327.1(participants)-328(continued)-323.5(their)-323.7(reg-)]TJ
0 -1.1116 TD
[(ular)-316.7(6-monthly)-310.9(study)-316.5(visits,)-309.5(but)-314.5(the)-315.6(NFHL)-312.4(investigators)-316.2(be-)]TJ
T*
[(gan)-257.9(collecting)-256.9(data)-254.5(on)-255.6(serum)-255.3(lipid)-253.6(proles,)-254(Framingham)-257.6(risk)]TJ
0 -1.1174 TD
[(score,)-362.4(and)-361.6(CRP)-356.6(as)-360.3(well)-363.8(as)-360.3(surrogate)-357.7(markers)-362.4(of)-359.3(cardiovas-)]TJ
0 -1.1116 TD
[(cular)-411.1(disease)-408.4(\(carotid)-414.5(intima)-406.8(media)-412.4(thickness)-409.5(\(cIMT\),)-410.6(and)]TJ
T*
[(coronary)-281.8(artery)-285.5(calcium)-283.4(\(CAC\).)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 62.022 308.6928 Tm
[(Study)-332.3(objectives)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 292.2519 Tm
[(We)-310.9(evaluated)-314.3(the)-309.9(association)-315.1(of)-307.4(statins)-314.1(with)-310.8(incidence)-314.3(of)]TJ
-1.0137 -1.1116 TD
[(myocardial)-378.8(infarction)-376.5(\()-81.7(MI\),)-376.2(stroke,)-374(and)-373.1(all-cause)-377.5(mortality)]TJ
T*
[(treated)-282.1(as)-285.4(a)-278.7(composite)-284.2(in)-278.8(an)-285.6(HIV)-281.5(infected)-283.2(cohort.)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 62.022 248.4283 Tm
[(Inclusion)-336.7(criteria)-332.5(and)-335.7(start)-335.6(of)-330.4(follow)-337.9(up)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 231.9873 Tm
[(In)-295.9(our)-297(analysis)-299(we)-298(included)-299.4(only)-292.5(those)-300.3(participants)-299.2(in)-296.1(the)]TJ
-1.0137 -1.1116 TD
[(NFHL)-185.7(study)-184(who)-182.7(at)-182(any)-183(point)-184.3(\(prior)-185.2(to)-180.9(or)-186.5(at)-182(baseline\))-186.2(initiated)]TJ
0 -1.1174 TD
[(cART)-279.4(\(678)-280.8(subjects\).)-280.5(Reecting)-285.2(the)-281.1(initiation)-277.9(of)-278.6(CARE,)-282.7(the)]TJ
0 -1.1116 TD
[(baseline)-432.8(in)-434.3(our)-429.5(study)-431.7(was)-431.4(September)-435(2000)-430.6(or)-428.4(the)-430.8(date)-433.1(of)]TJ
T*
[(initiation)-410.4(of)-405.3(cART)-406.1(\(whichever)-412.9(occurred)-409.7(later\).)-410(Lipid)-410.1(level)]TJ
T*
[(and)-390.4(other)-386.9(cardiovascular)-389.9(parameters)-396.9(were)-387.7(collected)-389.3(on)-388.1(the)]TJ
0 -1.1174 TD
[(NFHL)-364.3(participants)-368.3(beyond)-359.1(the)-367.5(CARE)-365.6(subset,)-362.3(and)-361.6(our)-360.4(ana-)]TJ
0 -1.1116 TD
[(lyzed)-221.1(group)-218.6(is)-221(therefore)-220.8(larger)-222.1(than)-218.8(the)-223.5(CARE)-221.6(subgroup)-215.9(\(499)]TJ
T*
[(subjects\).)-309.3(September)-308.3(2000)-298.2(was)-304.6(chosen)-308.2(to)-301.8(address)-309.1(a)-301.8(few)-304.8(im-)]TJ
0 -1.1174 TD
[(portant)-492.9(factors:)-500.7(Our)-488(analy)-8(zed)-489.4(population)-496.4(was)-494.7(selected)-497.3(to)]TJ
0 -1.1116 TD
[(represent)-307()50.8(modern)46.5()-300.6(HIV)-298.8(patients)-305.1(by)-301.7(both)-298.3(the)-298.3(cART)-308.2(agents)]TJ
T*
[(used)-345.2(for)-348.8(treatment)-349.1(and)-344.3(by)-342(the)-350.2(way)-345.2(they)-345.5(are)-345.4(monitored)-346.6(\(not)]TJ
0 -1.1174 TD
[(only)-528.7(for)-533.1(HIV)-529.1(but)-533.3(also)-529.6(for)-533.1(cardiovascular)-533.9(and)-528.6(metabolic)]TJ
0 -1.1116 TD
[(health\).)-290.2(Participants,)-291(who)-286.4(reported)-287.7(MI)-285.3(or)-290.2(stroke)-284.1(prior)-287.8(to)-284.6(ini-)]TJ
T*
[(tiation)-464.4(of)-457.2(cART)-463.7(were)-462.6(excluded,)-459.4(leaving)-465.3(480)-458.3(subjects.)-463.7(41)]TJ
0 -1.1174 TD
[(subjects)-206.8(had)-200.3(no)-198(follow)-203.5(up)-203.8(data)-202.7(and)-200.3(one)-200.3(additional)-203.9(subject)-205.9(was)]TJ
0 -1.1116 TD
[(excluded)-196.7(based)-197.7(on)-192.3(statin)-198(use)-194.3(for)-193.3(a)-192.3(period)-197.9(immediately)-197.1(prior)-195.6(to)]TJ
25.504 30.6186 TD
[(the)-448.1(baseline)-444.3(but)-441.2(not)-446.9(after,)-443.3(which)-445.4(would)-444.2(have)-444.5(confounded)]TJ
0 -1.1174 TD
[(baseline)-277.3(parameters)-270.2(and)-269.4(caused)-274.9(possible)-269(misclassication)-276.8(of)]TJ
0 -1.1116 TD
[(this)-407.7(subject.)-405.2(We)-408.8(thus)-401.8(identied)-409.9(a)-399.7(total)-410.2(of)-399.6(438)-406.5(participants)]TJ
T*
[(from)-282(NFHL)-283.7(cohort)-284.3(for)-279.7(our)-279.7(analysis)-281.7(\(Fig.)-284.2(1\).)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 313.0582 303.1936 Tm
[(Outcome)-337.1(denition,)-332.5(censoring)-336.4(criteria,)]TJ
0 -1.2203 TD
[(and)-335.7(follow-up)-336.2(time)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 275.8109 Tm
[(Our)-297.9(primary)-298.1(outcome)-299.4(was)-298.9(the)-298.3(composite)-301.5(endpoint)-298.2(of)-295.9(MI,)]TJ
-1.0137 -1.1116 TD
[(stroke,)-500.7(or)-497.5(all-cause)-504.2(mortality.)-500(Participant)-10.2(s)-497.3(eligible)-501.2(study)]TJ
0 -1.1174 TD
[(time)-416(continued)-409.9(until)-409.1(the)-413.5(time)-410.2(of)-405.3(the)-413.5(rst)-407.3(event)-416.9(within)-411(the)]TJ
0 -1.1116 TD
[(composite)-359.1(outcome,)-354.7(or)-353.5(until)-351.5(the)-355.9(time)-352.6(of)-353.5(censoring.)-355.4(Partici-)]TJ
T*
[(pants)-237(were)-232.2(censored)-236.7(at)-233.9(the)-229.2(last)-236(known)-231(study)-230.1(visit,)-233.8(except)-234.9(that)]TJ
0 -1.1174 TD
[(death)-192.3(was)-189.5(followed)-195.4(up)-186.5(for)-187.5(1)-191.2(year)-191(past)-189.8(the)-188.9(last)-189.9(visit.)-187.7(The)-190(period)]TJ
0 -1.1116 TD
[(of)-434.1(1)-427.3(year)-432.9(was)-431.4(chosen)-435(to)-428.5(match)-435.4(the)-430.8(predened)-433.7(spacing)-430.4(of)]TJ
T*
[(scheduled)-289.8(visits.)-286.5(cART)-285.1(interruption)-285.5(was)-287.4(not)-285.7(considered)-285.1(as)-285.4(a)]TJ
T*
[(basis)-282.9(for)-285.5(censoring.)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 313.0582 166.2236 Tm
[(Clinical)-340.5(data)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 149.7826 Tm
[(Clinical)-185.5(information)-187.6(was)-189.5(collected)-187.7(at)-182(baseline)-185.2(and)-188.8(every)-180.6(12)]TJ
-1.0137 -1.1116 TD
[(months)-330.3(\(initially)-335.5(every)-330.3(6)-329.4(months\).)-329.1(Laboratory)-331.4(data)-329.4(\(labora-)]TJ
0 -1.1174 TD
[(tory)-390.4(methods)-390.2(described)-387.7(elsewhere)]TJ
7.3823 0 0 6.5614 451.162 132.2646 Tm
(23)Tj
9.843 0 0 9.843 458.5322 127.8425 Tm
[(\))-387(were)-387.7(obtained)-391.5(during)]TJ
-14.7794 -1.1116 TD
[(the)-188.9(same)-186.3(visit,)-187.7(or)-180.7(as)-187.5(close)-186.3(as)-187.5(possible.)-186.1(Demographic)-190.6(data)-185.4(were)]TJ
T*
[(assesse)-10.4(d)-277.6(via)-281.1(interviewer-administered)-289.4(questionnai)-8.9(res.)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 313.0582 84.0189 Tm
[(Statistical)-342.4(analysis)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 67.5779 Tm
[(We)-264.8(chose)-266.8(the)-263.8(Cox)-263.5(proportional)-262.4(hazards)-270.2(method)-262.6(with)-264.7(time)]TJ
-1.0137 -1.1116 TD
[(varying)-273.9(covariates)-274.9(to)-267.3(evaluate)-278.7(the)-269.5(association)-274.8(of)-267.1(statins)-273.8(with)]TJ
ET
q
1 i
313.625 732.245 m
551.565 732.245 l
551.565 399.231 l
313.625 399.231 l
W n
q
238.023 0 0 333.014 313.625 399.231 cm
/Im1 Do
Q
Q
BT
/F7 1 Tf
9.845 0 0 9.845 371.4518 382.4503 Tm
[(FIG.)-336.7(1.)]TJ
/F4 1 Tf
4.1174 0 TD
[(Study)-333.2(ow)-331.9(diagram.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(308)Tj
47.5673 0 TD
[(KRSAK)-331.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
43 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? o=X[`8!BQE(Wib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z9ib wӛV/L7z8^[yK`JPsf͛6lٳf͛6lٳf͛6lٳf͛6l_L/0 tdg6lYyf͛6lYyf͕+6-i[ X c=_͛6lٳf͛6lٳf͛6lٳf͛6lٳǿ0 1 f͛6^Vlٳf͛6lٳefm?Lg#~Ccf͛6lٳf͛6lٳf͛6lٳf͛6l_L/0 t#yf͕6lYf͗6lR {??V;6lٳf͛6lٳf͛6lٳf͛6lٳf~e K256lٳef͛6lٳf͛+/6lR {??V;6lٳf͛6lٳf͛6lٳf͛6lٳfe K276lyYyYyf͛6V^VlXo c ݯ~vlٳf͛6lٳf͛6lٳf͛6lٳf͞= Ʌdk/R\MŧNnVFQd,*|f\j=}VŤ},Ouaq~IJ9G/H=+F5;*dmJ[$0*J(]w5kN쑍TDefy%gsuI⹒fbh9LD%w?f L'I @U2vJSyg_{pְ5u+ާap,vftL!It"4rCկ-B5"#@;w_ZYTV/Q9y\tvG